Genetic polymorphisms in aquaporin 1 as risk factors for malignant mesothelioma and biomarkers of response to cisplatin treatment

1Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med 1960; 17: 260-71. PMID: 13782506 Wagner JC Sleggs CA Marchand P Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province Br J Ind Med 1960 17 26071 PMID: 13782506Search in Google Scholar

2Zellos L, Christiani DC. Epidemiology, biologic behavior, and natural history of mesothelioma. Thorac Surg Clin 2004; 14: 469-77. doi: 10.1016/j. thorsurg.2004.06.011. Zellos L Christiani DC Epidemiology, biologic behavior, and natural history of mesothelioma Thorac Surg Clin 2004 14 46977 10.1016/jthorsurg.2004.06.011Open DOISearch in Google Scholar

3Maule MM, Magnani C, Dalmasso P, Mirabelli D, Merletti F, Biggeri A. Modeling mesothelioma risk associated with environmental asbestos exposure. Environ Health Perspect 2007; 115: 1066-71. doi: 10.1289/ehp.9900 Maule MM Magnani C Dalmasso P Mirabelli D Merletti F Biggeri A Modeling mesothelioma risk associated with environmental asbestos exposure Environ Health Perspect 2007 115 106671 10.1289/ehp.9900Open DOISearch in Google Scholar

4Magnani C, Dalmasso P, Biggeri A, Ivaldi C, Mirabelli D, Terracini B. Increased risk of malignant mesothelioma of the pleura after residential or domestic exposure to asbestos: a case-control study in Casale Monferrato, Italy. Environ Health Perspect 2001; 109: 915-9. doi: 10.1289/ehp.01109915 Magnani C Dalmasso P Biggeri A Ivaldi C Mirabelli D Terracini B Increased risk of malignant mesothelioma of the pleura after residential or domestic exposure to asbestos: a case-control study in Casale Monferrato, Italy Environ Health Perspect 2001 109 9159 10.1289/ehp.01109915Open DOISearch in Google Scholar

5Klebe S, Griggs K, Cheng Y, Driml J, Henderson DW, Reid G. Blockade of aquaporin 1 inhibits proliferation, motility, and metastatic potential of mesothelioma in vitro but not in an in vivo model. Dis Markers 2015; 2015: 286719. doi: 10.1155/2015/286719 Klebe S Griggs K Cheng Y Driml J Henderson DW Reid G Blockade of aquaporin 1 inhibits proliferation, motility, and metastatic potential of mesothelioma in vitro but not in an in vivo model Dis Markers 2015 2015 286719 10.1155/2015/286719Open DOISearch in Google Scholar

6Bridda A, Padoan I, Mencarelli R, Frego M. Peritoneal mesothelioma: a review. MedGenMed 2007; 9: 32. PMID: 17955087 Bridda A Padoan I Mencarelli R Frego M Peritoneal mesothelioma: a review MedGenMed 2007 9 32 PMID: 17955087Search in Google Scholar

7International Agency for Research on Cancer (IARC). IARC Working Group. Asbestos. IARC monographs on the evaluation of carcinogenic risks to humans Lyon: IARC; 1972. International Agency for Research on Cancer (IARC) IARC Working Group. Asbestos. IARC monographs on the evaluation of carcinogenic risks to humans Lyon IARC 1972Search in Google Scholar

8Brodkin CA, Rosenstock L. Asbestos and asbestos-related pleural disease. In: Rosenstock L, Cullen MR, Brodkin CA, Redlich CA, editors. Textbook of clinical occupational and environmental medicine 2^nd edition. Philadelphia: Elsevier Saunders; 2005. p. 364-77. Brodkin CA Rosenstock L Asbestos and asbestos-related pleural disease Rosenstock L Cullen MR Brodkin CA Redlich CA Textbook of clinical occupational and environmental medicine 2^nd edition Philadelphia Elsevier Saunders 2005 36477Search in Google Scholar

9Wagner GR, Hearl FJ. Mineral dust: asbestos, silica, coal, manufactured fibers. In: Rosenstock L, Cullen MR, Brodkin CA, Redlich CA, editors. Textbook of clinical occupational and environmental medicine 2^nd edition. Philadelphia: Elsevier Saunders; 2005. p. 1073-8. Wagner GR Hearl FJ Mineral dust: asbestos, silica, coal, manufactured fibers Rosenstock L Cullen MR Brodkin CA Redlich CA Textbook of clinical occupational and environmental medicine 2^nd edition Philadelphia Elsevier Saunders 2005 10738Search in Google Scholar

10Rom WN. Asbestosis, pleural fibrosis, and lung cancer. In: Rom WN, Markowitz SB, eds. Environmental and occupational medicine 4^th edition. Philadelphia: Wolters Kluwer, Lippincott Williams&Wilkins; 2007: p. 298316. Rom WN Asbestosis, pleural fibrosis, and lung cancer Rom WNMarkowitz SB Environmental and occupational medicine 4^th edition Philadelphia Wolters Kluwer, Lippincott Williams&Wilkins 2007 298316Search in Google Scholar

11Driml J, Pulford E, Moffat D, Karapetis C, Kao S, Griggs K, et al. Usefulness of aquaporin 1 as a prognostic marker in a prospective cohort of malignant mesotheliomas. Int J Mol Sci 2016; 17(7). pii: E1041. doi: 10.3390/ijms17071041. Driml J Pulford E Moffat D Karapetis C Kao S Griggs K Usefulness of aquaporin 1 as a prognostic marker in a prospective cohort of malignant mesotheliomas Int J Mol Sci 2016 177 pii: E1041 10.3390/ijms17071041Open DOISearch in Google Scholar

12Zadnik V, Primic Zakelj M, Lokar K, Jarm K, Ivanus U, Zagar T. Cancer burden in slovenia with the time trends analysis. Radiol Oncol 2019; 53(1): 96104.7; 51: 47-55. doi:10.1515/raon-2017-0008. Zadnik V Primic Zakelj M Lokar K Jarm K Ivanus U Zagar T Cancer burden in slovenia with the time trends analysis Radiol Oncol 2019 531 96104.7; 51 4755 10.1515/raon-2017-0008Open DOISearch in Google Scholar

13Goricar K, Kovac V, Franko A, Dodic-Fikfak M, Dolzan V. Serum survivin levels and outcome of chemotherapy in patients with malignant mesothelioma. Dis Markers 2015; 2015: 316739. doi:10.1155/2015/316739 Goricar K Kovac V Franko A Dodic-Fikfak M Dolzan V Serum survivin levels and outcome of chemotherapy in patients with malignant mesothelioma Dis Markers 2015 2015 316739 10.1155/2015/316739Open DOISearch in Google Scholar

14Weber DG, Casjens S, Johnen G, Bryk O, Raiko I, Pesch B, et al. Combination of MiR-103a-3p and mesothelin improves the biomarker performance of malignant mesothelioma diagnosis. PLoS One 2014; 9: e114483. doi: 10.1371/journal.pone.0114483 Weber DG Casjens S Johnen G Bryk O Raiko I Pesch B Combination of MiR-103a-3p and mesothelin improves the biomarker performance of malignant mesothelioma diagnosis PLoS One 2014 9 e114483 10.1371/journal.pone.0114483Open DOISearch in Google Scholar

15Franko A, Dolzan V, Kovac V, Arneric N, Dodic-Fikfak M. Soluble mesothelin-related peptides levels in patients with malignant mesothelioma. Dis Markers 2012; 32: 123-31. doi: 10.3233/DMA-2011-0866 Franko A Dolzan V Kovac V Arneric N Dodic-Fikfak M Soluble mesothelin-related peptides levels in patients with malignant mesothelioma Dis Markers 2012 32 12331 10.3233/DMA-2011-0866Open DOISearch in Google Scholar

16Kovac V, Dodic-Fikfak M, Arneric N, Dolzan V, Franko A. Fibulin-3 as a biomarker of response to treatment in malignant mesothelioma. Radiol Oncol 2019; 53(1): 96-104.5; 49: 279-85. doi: 10.1515/raon-2015-0019 Kovac V Dodic-Fikfak M Arneric N Dolzan V Franko A Fibulin-3 as a biomarker of response to treatment in malignant mesothelioma Radiol Oncol 2019 531 96-104.5; 49 27985 10.1515/raon-2015-0019Open DOISearch in Google Scholar

17Neri M, Ugolini D, Dianzani I, Gemignani F, Landi S, Cesario A, et al. Genetic susceptibility to malignant pleural mesothelioma and other asbestos-associated diseases. Mutat Res 2008; 659: 126-36. doi:10.1016/j.mr-rev.2008.02.002 Neri M Ugolini D Dianzani I Gemignani F Landi S Cesario A Genetic susceptibility to malignant pleural mesothelioma and other asbestos-associated diseases Mutat Res 2008 659 12636 10.1016/j.mr-rev.2008.02.002Open DOISearch in Google Scholar

18Erculj N, Kovac V, Hmeljak J, Franko A, Dodic-Fikfak M, Dolzan V. DNA repair polymorphisms and treatment outcomes of patients with malignant mesothelioma treated with gemcitabine-platinum combination chemotherapy. J Thorac Oncol 2012; 7: 1609-17. doi: 10.1097/JTO.0b013e3182653d31 Erculj N Kovac V Hmeljak J Franko A Dodic-Fikfak M Dolzan V DNA repair polymorphisms and treatment outcomes of patients with malignant mesothelioma treated with gemcitabine-platinum combination chemotherapy J Thorac Oncol 2012 7 160917 10.1097/JTO.0b013e3182653d31Open DOISearch in Google Scholar

19Franko A, Kotnik N, Goricar K, Kovac V, Dodic-Fikfak M, Dolzan V. The influence of genetic variability on the risk of developing malignant mesothelioma. Radiol Oncol 2019; 53(1): 96-104.8; 52: 105-11. doi:10.2478/raon-2018-0004 Franko A Kotnik N Goricar K Kovac V Dodic-Fikfak M Dolzan V The influence of genetic variability on the risk of developing malignant mesothelioma Radiol Oncol 2019 531 96-104.8; 52 10511 10.2478/raon-2018-0004Open DOISearch in Google Scholar

20Khella MS, Salem AM, Abdel-Rahman O, Saad AS. The association between the FTO rs9939609 variant and malignant pleural mesothelioma risk: a case-control study. Genet Test Mol Biomarkers 2018; 22: 79-84. doi: 10.1089/gtmb.2017.0146 Khella MS Salem AM Abdel-Rahman O Saad AS The association between the FTO rs9939609 variant and malignant pleural mesothelioma risk: a case-control study Genet Test Mol Biomarkers 2018 22 7984 10.1089/gtmb.2017.0146Open DOISearch in Google Scholar

21Strbac D, Goricar K, Dolzan V, Kovac V. Matrix metalloproteinases polymorphisms as baseline risk predictors in malignant pleural mesothelioma. Radiol Oncol 2019; 53(1): 96-104.8; 52: 160-6. doi: 10.2478/raon-2018-0005 Strbac D Goricar K Dolzan V Kovac V Matrix metalloproteinases polymorphisms as baseline risk predictors in malignant pleural mesothelioma Radiol Oncol 2019 531 96-104.8; 52 1606 10.2478/raon-2018-0005Open DOISearch in Google Scholar

22Strbac D, Goricar K, Dolzan V, Kovac V. Matrix metalloproteinases polymorphisms as prognostic biomarkers in malignant pleural mesothelioma. Dis Markers 2017; 2017: 8069529. doi: 10.1155/2017/8069529 Strbac D Goricar K Dolzan V Kovac V Matrix metalloproteinases polymorphisms as prognostic biomarkers in malignant pleural mesothelioma Dis Markers 2017 2017 8069529 10.1155/2017/8069529Open DOISearch in Google Scholar

23El-Hamamsy M, Ghali RR, Saad AS, Shaheen SM, Salem AM. FAS and FASL genetic polymorphisms impact on clinical outcome of malignant pleural mesothelioma. Onco Targets Ther 2016;9:6857-63. doi: 10.2147/OTT. S115631 El-Hamamsy M Ghali RR Saad AS Shaheen SM Salem AM FAS and FASL genetic polymorphisms impact on clinical outcome of malignant pleural mesothelioma Onco Targets Ther 20169685763 10.2147/OTT S115631Open DOISearch in Google Scholar

24Goricar K, Kovac V, Dolzan V. Polymorphisms in translesion polymerase genes influence treatment outcome in malignant mesothelioma. Pharmacogenomics 2014; 15: 941-50. doi: 10.2217/pgs.14.14 Goricar K Kovac V Dolzan V Polymorphisms in translesion polymerase genes influence treatment outcome in malignant mesothelioma Pharmacogenomics 2014 15 94150 10.2217/pgs.14.14Open DOISearch in Google Scholar

25Cao XC, Zhang WR, Cao WF, Liu BW, Zhang F, Zhao HM, et al. Aquaporin3 is required for FGF-2-induced migration of human breast cancers. PLoS One 2013; 8: e56735. doi: 10.1371/journal.pone.0056735 Cao XC Zhang WR Cao WF Liu BW Zhang F Zhao HM Aquaporin3 is required for FGF-2-induced migration of human breast cancers PLoS One 2013 8 e56735 10.1371/journal.pone.0056735Open DOISearch in Google Scholar

26Hwang I, Jung SI, Hwang EC, Song SH, Lee HS, Kim SO, et al. Expression and localization of aquaporins in benign prostate hyperplasia and prostate cancer. Chonnam Med J 2012; 48: 174-8. doi: 10.4068/cmj.2012.48.3.174 Hwang I Jung SI Hwang EC Song SH Lee HS Kim SO Expression and localization of aquaporins in benign prostate hyperplasia and prostate cancer Chonnam Med J 2012 48 1748 10.4068/cmj.2012.48.3.174Open DOISearch in Google Scholar

27Jung HJ, Park JY, Jeon HS, Kwon TH. Aquaporin-5: a marker protein for proliferation and migration of human breast cancer cells. PLoS One 2011; 6: e28492. doi: 10.1371/journal.pone.0028492 Jung HJ Park JY Jeon HS Kwon TH Aquaporin-5: a marker protein for proliferation and migration of human breast cancer cells PLoS One 2011 6 e28492 10.1371/journal.pone.0028492Open DOISearch in Google Scholar

28Chen R, Shi Y, Amiduo R, Tuokan T, Suzuk L. Expression and prognostic value of aquaporin 1, 3 in cervical carcinoma in women of Uygur ethnicity from Xinjiang, China. PLoS One 2014; 9: e98576. doi: 10.1371/journal. pone.0098576 Chen R Shi Y Amiduo R Tuokan T Suzuk L Expression and prognostic value of aquaporin 1, 3 in cervical carcinoma in women of Uygur ethnicity from Xinjiang, China PLoS One 2014 9 e98576 10.1371/journal pone.0098576Open DOISearch in Google Scholar

29Jagirdar RM, Apostolidou E, Molyvdas PA, Gourgoulianis KI, Hatzoglou C, Zarogiannis SG. Influence of AQP1 on cell adhesion, migration, and tumor sphere formation in malignant pleural mesothelioma is substratum- and histological-type dependent. Am J Physiol Lung Cell Mol Physiol 2016; 310: L489-95. doi: 10.1152/ajplung.00410.2015 Jagirdar RM Apostolidou E Molyvdas PA Gourgoulianis KI Hatzoglou C Zarogiannis SG Influence of AQP1 on cell adhesion, migration, and tumor sphere formation in malignant pleural mesothelioma is substratum- and histological-type dependent Am J Physiol Lung Cell Mol Physiol 2016 310 L48995 10.1152/ajplung.00410.2015Open DOISearch in Google Scholar

30Saadoun S, Papadopoulos MC, Hara-Chikuma M, Verkman AS. Impairment of angiogenesis and cell migration by targeted aquaporin-1 gene disruption. Nature 2005; 434: 786-92. doi: 10.1038/nature03460 Saadoun S Papadopoulos MC Hara-Chikuma M Verkman AS Impairment of angiogenesis and cell migration by targeted aquaporin-1 gene disruption Nature 2005 434 78692 10.1038/nature03460Open DOISearch in Google Scholar

31Kao SC, Armstrong N, Condon B, Griggs K, McCaughan B, Maltby S, et al. Aquaporin 1 is an independent prognostic factor in pleural malignant mesothelioma. Cancer 2012; 118: 2952-61. doi: 10.1002/cncr.26497 Kao SC Armstrong N Condon B Griggs K McCaughan B Maltby S Aquaporin 1 is an independent prognostic factor in pleural malignant mesothelioma Cancer 2012 118 295261 10.1002/cncr.26497Open DOISearch in Google Scholar

32Qin F, Zhang H, Shao Y, Liu X, Yang L, Huang Y, et al. Expression of aquaporin1, a water channel protein, in cytoplasm is negatively correlated with prognosis of breast cancer patients. Oncotarget 2016; 7: 8143-54. doi: 10.18632/oncotarget.6994 Qin F Zhang H Shao Y Liu X Yang L Huang Y Expression of aquaporin1, a water channel protein, in cytoplasm is negatively correlated with prognosis of breast cancer patients Oncotarget 2016 7 814354 10.18632/oncotarget.6994Open DOISearch in Google Scholar

33Imredi E, Toth B, Doma V, Barbai T, Raso E, Kenessey I, et al. Aquaporin 1 protein expression is associated with BRAF V600 mutation and adverse prognosis in cutaneous melanoma. Melanoma Res 2016; 26: 254-60. doi: 10.1097/CMR.0000000000000243 Imredi E Toth B Doma V Barbai T Raso E Kenessey I Aquaporin 1 protein expression is associated with BRAF V600 mutation and adverse prognosis in cutaneous melanoma Melanoma Res 2016 26 25460 10.1097/CMR.0000000000000243Open DOISearch in Google Scholar

34Liu J, Zhang WY, Ding DG. Expression of aquaporin 1 in bladder uroepithelial cell carcinoma and its relevance to recurrence. Asian Pac J Cancer Prev 2015; 16: 3973-6. Liu J Zhang WY Ding DG Expression of aquaporin 1 in bladder uroepithelial cell carcinoma and its relevance to recurrence Asian Pac J Cancer Prev 2015 16 39736Search in Google Scholar

35Lehnerdt GF, Bachmann HS, Adamzik M, Panic A, Koksal E, Weller P, et al. AQP1, AQP5, Bcl-2 and p16 in pharyngeal squamous cell carcinoma. J Laryngol Otol 2015; 129: 580-6. doi: 10.1017/S002221511500119X Lehnerdt GF Bachmann HS Adamzik M Panic A Koksal E Weller P AQP1, AQP5, Bcl-2 and p16 in pharyngeal squamous cell carcinoma J Laryngol Otol 2015 129 5806 10.1017/S002221511500119XOpen DOISearch in Google Scholar

36Jagirdar R, Solenov EI, Hatzoglou C, Molyvdas PA, Gourgoulianis KI, Zarogiannis SG. Gene expression profile of aquaporin 1 and associated interactors in malignant pleural mesothelioma. Gene 2013; 517: 99-105. doi: 10.1016/j.gene.2012.12.075 Jagirdar R Solenov EI Hatzoglou C Molyvdas PA Gourgoulianis KI Zarogiannis SG Gene expression profile of aquaporin 1 and associated interactors in malignant pleural mesothelioma Gene 2013 517 99105 10.1016/j.gene.2012.12.075Open DOISearch in Google Scholar

37Henderson DW, Reid G, Kao SC, van Zandwijk N, Klebe S. Challenges and controversies in the diagnosis of malignant mesothelioma: Part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and micro-RNA. J Clin Pathol 2013; 66: 854-61. doi: 10.1136/jclinpath-2013-201609 Henderson DW Reid G Kao SC van Zandwijk N Klebe S Challenges and controversies in the diagnosis of malignant mesothelioma: Part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and micro-RNA J Clin Pathol 2013 66 85461 10.1136/jclinpath-2013-201609Open DOISearch in Google Scholar

38Yool AJ, Brown EA, Flynn GA. Roles for novel pharmacological blockers of aquaporins in the treatment of brain oedema and cancer. Clin Exp Pharmacol Physiol 2010; 37: 403-9. doi: 10.1111/j.1440-1681.2009.05244.x Yool AJ Brown EA Flynn GA Roles for novel pharmacological blockers of aquaporins in the treatment of brain oedema and cancer Clin Exp Pharmacol Physiol 2010 37 4039 10.1111/j.1440-1681.2009.05244.xOpen DOISearch in Google Scholar

39El Hindy N, Rump K, Lambertz N, Zhu Y, Frey UH, Bankfalvi A, et al. The functional aquaporin 1 -783G/C-polymorphism is associated with survival in patients with glioblastoma multiforme. J Surg Oncol 2013; 108: 492-8. doi: 10.1002/jso.23421 El Hindy N Rump K Lambertz N Zhu Y Frey UH Bankfalvi A The functional aquaporin 1 -783G/C-polymorphism is associated with survival in patients with glioblastoma multiforme J Surg Oncol 2013 108 4928 10.1002/jso.23421Open DOISearch in Google Scholar

40Fabrega E, Berja A, Garcia-Unzueta MT, Guerra-Ruiz A, Cobo M, Lopez M, et al. Influence of aquaporin-1 gene polymorphism on water retention in liver cirrhosis. Scand J Gastroenterol 2011; 46: 1267-74. doi: 10.3109/00365521.2011.603161 Fabrega E Berja A Garcia-Unzueta MT Guerra-Ruiz A Cobo M Lopez M Influence of aquaporin-1 gene polymorphism on water retention in liver cirrhosis Scand J Gastroenterol 2011 46 126774 10.3109/00365521.2011.603161Open DOISearch in Google Scholar

41Saunders CJ, Posthumus M, O’Connell K, September AV, Collins M. A variant within the AQP1 3’-untranslated region is associated with running performance, but not weight changes, during an Ironman Triathlon. J Sports Sci 2015; 33: 1342-8. doi: 10.1080/02640414.2014.989535 Saunders CJ Posthumus M O’Connell K September AV Collins M A variant within the AQP1 3’-untranslated region is associated with running performance, but not weight changes, during an Ironman Triathlon J Sports Sci 2015 33 13428 10.1080/02640414.2014.989535Open DOISearch in Google Scholar

42Elliott L, Ashley-Koch AE, De Castro L, Jonassaint J, Price J, Ataga KI, et al. Genetic polymorphisms associated with priapism in sickle cell disease. Br J Haematol 2007; 137 262-7. doi: 10.1111/j.1365-2141.2007.06560.x Elliott L Ashley-Koch AE De Castro L Jonassaint J Price J Ataga KI Genetic polymorphisms associated with priapism in sickle cell disease Br J Haematol 2007 137 2627 10.1111/j.1365-2141.2007.06560.xOpen DOISearch in Google Scholar

43Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-16. PMID: 10655437 Therasse P Arbuck SG Eisenhauer EA Wanders J Kaplan RS Rubinstein L New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 2000 92 20516 PMID: 10655437Search in Google Scholar

44National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0. [cited 2018 Feb 15] Available at: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0 [cited 2018 Feb 15] Available at https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htmSearch in Google Scholar

45Erculj N, Kovac V, Hmeljak J, Franko A, Dodic-Fikfak M, Dolzan V. The influence of gemcitabine pathway polymorphisms on treatment outcome in patients with malignant mesothelioma. Pharmacogenet Genomics 2012; 22: 58-68. doi: 10.1097/FPC.0b013e32834e3572 Erculj N Kovac V Hmeljak J Franko A Dodic-Fikfak M Dolzan V The influence of gemcitabine pathway polymorphisms on treatment outcome in patients with malignant mesothelioma Pharmacogenet Genomics 2012 22 5868 10.1097/FPC.0b013e32834e3572Open DOISearch in Google Scholar

46Erculj N, Kovac V, Hmeljak J, Dolzan V. The influence of platinum pathway polymorphisms on the outcome in patients with malignant mesothelioma. Ann Oncol 2012; 23: 961-7. doi: 10.1093/annonc/mdr324 Erculj N Kovac V Hmeljak J Dolzan V The influence of platinum pathway polymorphisms on the outcome in patients with malignant mesothelioma Ann Oncol 2012 23 9617 10.1093/annonc/mdr324Open DOISearch in Google Scholar

47Goricar K, Kovac V, Dolzan V. Polymorphisms in folate pathway and pemetrexed treatment outcome in patients with malignant pleural mesothelioma. Radiol Oncol 2019; 53(1): 96-104.4; 48: 163-72. doi: 10.2478/raon-2013-0086 Goricar K Kovac V Dolzan V Polymorphisms in folate pathway and pemetrexed treatment outcome in patients with malignant pleural mesothelioma Radiol Oncol 2019 531 96-104.4; 48: 163-72 10.2478/raon-2013-0086Open DOISearch in Google Scholar

48Goricar K, Kovac V, Dolzan V. Clinical-pharmacogenetic models for personalized cancer treatment: application to malignant mesothelioma. Sci Rep 2017; 7: 46537. doi: 10.1038/srep46537 Goricar K Kovac V Dolzan V Clinical-pharmacogenetic models for personalized cancer treatment: application to malignant mesothelioma Sci Rep 2017 7 46537 10.1038/srep46537Open DOISearch in Google Scholar

49Dimasi DP, Burdon KP, Hewitt AW, Savarirayan R, Healey PR, Mitchell P, et al. Candidate gene study to investigate the genetic determinants of normal variation in central corneal thickness. Mol Vis 2010; 16: 562-9. PMID: 20360993 Dimasi DP Burdon KP Hewitt AW Savarirayan R Healey PR Mitchell P Candidate gene study to investigate the genetic determinants of normal variation in central corneal thickness Mol Vis 2010 16 5629 PMID: 20360993Search in Google Scholar

50Vidan-Jeras B, Jurca B, Dolžan V, Jeras M, Breskvar K, Bohinjec M. »Caucasian slovenian normal«, HLA 1998 In: Terasaki PI, Gjerston DW, editors. Lenexa: American Society for Histocompatibility and Immunogenetics; 1998. p. 180-1. Vidan-Jeras B Jurca B Dolžan V Jeras M Breskvar K Bohinjec M »Caucasian slovenian normal«, HLA 1998 Terasaki PI Gjerston DW Lenexa American Society for Histocompatibility and Immunogenetics 1998 1801Search in Google Scholar

51Mizzi C, Dalabira E, Kumuthini J, Dzimiri N, Balogh I, Basak N, et al. Correction: a European spectrum of pharmacogenomic biomarkers: implications for clinical pharmacogenomics. PLoS One 2017; 12: e0172595. doi: 10.1371/journal.pone.0162866.]. Mizzi C Dalabira E Kumuthini J Dzimiri N Balogh I Basak N Correction: a European spectrum of pharmacogenomic biomarkers: implications for clinical pharmacogenomics PLoS One 2017 12 e0172595 10.1371/journal.pone.0162866.]Open DOISearch in Google Scholar